Japan has approved GSK’s Exdensur (depemokimab) for severe or refractory bronchial asthma and chronic rhinosinusitis with nasal polyps, based on positive Phase III SWIFT and ANCHOR trials. The twice-yearly dosing regimen demonstrated safety and efficacy on top of standard of care, paving the way for a 2026 launch in Japan.